With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Jonathan Cushing, Head of Global Health, Transparency International
Javier Guzman, Director of Global Health Policy and Senior Policy Fellow, Center for Global Development
Jillian Kohler, Director, WHO Collaborating Centre for Governance, Transparency and Accountability in the Pharmaceutical Sector
Nicaise Ndembi, Senior Science Advisor, Africa Centres for Disease Control and Prevention
Natalie Rhodes, Policy Officer, Transparency International
David Wilson, Program Director, Health, Nutrition and Population, World Bank
Tom Wright, Senior Programme Officer, Transparency International
Janeen Madan Keller, Assistant Director of Global Health Policy and Senior Policy Analyst, Center for Global Development
ABOUT THE EVENT
Policymakers around the world have made the expeditious deployment of safe and effective COVID-19 vaccines a top priority in order to bring the pandemic under control. But how much information about COVID-19 purchasing agreements is actually available in the public domain? And how can data sharing and contract publication help policymakers decide how much vaccine countries should buy, who should pay, and how they should be delivered and distributed?
Join the Center for Global Development and Transparency International for a discussion on opportunities for greater transparency in COVID-19 vaccine development and procurement, building on new research from Transparency International and the WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector on transparency in COVID-19 vaccine clinical trials and contracting. Speakers will highlight the key risks of limited information on vaccine development and procurement and examine how to move toward more systematic and strategic approaches for improved global access and equity.